Google Halts UK YouTube TV Measurement Service After Legal Action 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
RESEARCH TRIANGLE PARK, N.C., May 23, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of 7,781,564 shares of common stock at a public offering price of $15.00 per share, including 781,564 shares sold pursuant to the partial exercise of the underwriters’ option to purchase additional shares. G1 Therapeutics received approximately $108.6 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses. The shares began trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.”
J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow acted as co-managers for the offering.
A registration statement relating to these securities was filed with and has been declared effective by the Securities and Exchange Commission on May 16, 2017. The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
Contacts Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
